CureVac’s experimental Kovid-19 vaccine accelerated immune response in humans, putting the German biotech company on track to begin large-scale testing this year on Monday, as the race to end the epidemic began.
“We are very encouraged by the interim phase I data,” Chief Executive Officer Franz-Werner Haas said in a statement.
Click here for complete coverage of Kovid-19
The biotech firm is using the so-called messenger RNA (mRNA) approach, as modern as well as BioNotech and its partner Pfizer, although they began large-scale testing on humans in late July.
CureVac said its potential vaccine, known as CVnCoV, was generally well tolerated and the results strongly supported the company’s plans to launch the final phase of testing on humans before the end of the year did.
CureVac – backed by German biotech investor Detmar Hopper, the Gates Foundation and GlaxoSmithKline – said volunteers developed a level of neutralizing antibodies equivalent to those recovering from a severe case of Kovid-19.
The epidemic, which has claimed more than 1.1 million lives globally, has begun a scramble to develop a vaccine on humans with approximately 45 experimental compounds.
AstraZeneca of Britain, working with the University of Oxford, is also among the leading contenders with the results of a final test due later this year, but their candidates are based on another virus, rather than mRNA, in the body for immunity Genetic instructions.
Also read Britain launches quick review for AstraZeneca’s potential Kovid-19 vaccine
America’s top infectious disease specialist Anthony Fauci said Thursday that the first dose of a safe and effective coronavirus vaccine would become available to some high-risk Americans in late December or early January.
CureVac can be expected to be vaccinated at a much lower dose than its mRNA competitors because it has raised the highest concentration of two to 12 micrograms per shot – 2 to 12 micrograms per shot – for its potential Phase III trial.
BioNTech and Pfizer have stated that the 30 microgram shot they selected in their late-stage trial was shown to produce antibody levels above the level previously registered in those recovered from Kovid-19.
Modern, which is similar to biotech, hopes to get the first efficacy data from this month’s mass test, testing a 100 μg shot that was also shown to trigger an antibody response over recovered patients. is.
CureVac, which went public on the Nasdaq Exchange in August, said that its Phase I study has so far enrolled more than 250 healthy individuals aged 18 to 60 in Germany and Belgium.
It has been stated that its vaccine generates T cells against coronovirus, another important indicator of an effective immune system arsenal, but more analysis was ongoing.
It has been said that its two-dose diet has side effects after the second injection and includes tiredness, headaches, chills, muscle aches, and to a lesser extent fever.
These conditions “resolved rapidly, usually within 24 to 48 hours”.
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ